Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mankind PharmaBOM:543904 +0.51%91 Days Payable is 127.71 as of Mar. 2026, which is 1% below its 10-year median of 128.42. GuruFocus rates BOM:543904 with a GF Score™ of 91/100 and a GF Value™ of ₹2,939.56 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 925 Drug Manufacturers companies, Mankind Pharma ranks better than 63.24% on this metric.
The historical rank and industry rank for Mankind Pharma's Days Payable or its related term are showing as below:
BOM:543904'
s Days Payable Range Over the Past 10 Years
Min: 97.69 Med: 128.42 Max: 141.4
Current: 113.38
During the past 7 years, Mankind Pharma's highest Days Payable was 141.40. The lowest was 97.69. And the median was 128.42.
BOM:543904's Days Payable is ranked better than 63.24% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:543904: 113.38
Mankind Pharma's Days Payable
increased
from Mar. 2025 (118.15) to Mar. 2026 (127.71).
It may suggest that Mankind Pharmadelayed paying its suppliers.
Mankind Pharma Days Payable Related Terms
Mankind Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Mankind Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mankind Pharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Mankind Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Mankind Pharma's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mankind Pharma (BOM:543904) has a Days Payable of 127.71 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mankind Pharma and its competitors. This is near median its historical median of 128.42. Over the past decade, Mankind Pharma's Days Payable has ranged from 97.69 to 141.40. According to the industry distribution chart, Mankind Pharma ranks #340 out of 925 companies in the Drug Manufacturers industry, placing it in the top 36.8%.
Is Mankind Pharma's Days Payable too high?
Mankind Pharma's current Days Payable of 127.71 is near median its 10-year median of 128.42. Over the past 10 years, this metric has ranged from a low of 97.69 to a high of 141.40. The Drug Manufacturers industry median Days Payable is 90.38. Mankind Pharma's value of 127.71 is 41.3% above this industry median. Based on the distribution chart, Mankind Pharma ranks #340 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Mankind Pharma has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mankind Pharma ranks #340 out of 925 companies for Days Payable. This puts Mankind Pharma in the upper half of its industry. The industry median Days Payable is 90.38. Mankind Pharma's value of 127.71 is 41.3% above this benchmark. Historically, Mankind Pharma's own Days Payable has ranged from 97.69 to 141.40 over the past decade. While the company's 10-year median is 128.42 vs. the industry median of 90.38, Mankind Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mankind Pharma's current Days Payable of 127.71 is 41.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mankind Pharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mankind Pharma's current Days Payable is 127.71, which is near median its own 10-year median of 128.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (BOM:543904) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,939.56, compared to a current price of ₹2,557.10 — trading 13% below its estimated fair value. The current Days Payable is 127.71, which is near median its 10-year median of 128.42 and 41.3% above the Drug Manufacturers industry median of 90.38. Mankind Pharma's overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Mankind Pharma (BOM:543904), the current Days Payable is 127.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mankind Pharma (BOM:543904) Overvalued in 2026?
Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued.
The current stock price of ₹2,557.10 is trading 13% below its estimated GF Value™ of ₹2,939.56.
GuruFocus considers Mankind Pharma to be Modestly Undervalued.
Key valuation signals for BOM:543904:
Days Payable: 127.71 (near median its 10-year median of 128.42)
GF Value™: ₹2,939.56 vs. price of ₹2,557.10 (13% below fair value)
Industry Position: 41.3% above the Drug Manufacturers median (#340 of 925)
No single metric tells the full story. See the BOM:543904 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
91GF Score
Get the complete analysis for BOM:543904
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543904 has been successfully added to your 
